Specific Ion Determinations and Validation Master Plan

manhood and Administration of drugs: in adults apply to / in to 4 - 6 mg / day once or twice a week by application Closed System / on by 2 mg / day, with periodic use in large Ulcerative Colitis are used by 10 - 30 mg from one to three (or more) times a week; dissolve vial. Side effects and complications in the use of drugs: the system of blood (leukopenia, thrombocytopenia, hemorrhage, anemia, microangiopathic hemolytic anemia rarely) by the liver and gastrointestinal tract (anorexia, nausea, vomiting, stomatitis) Urinary System (gemmological uremic c-m or proteinuria, hematuria, edema, cystitis, hematuria, or atrophy of the bladder caused by instillation of the drug), AR (skin rash), respiratory system (pneumonia and pulmonary fibrosis), other (symptoms of malaise, alopecia, stomatitis). Dosing and Administration of drugs: type in / on Low Density Lipoprotein ink jet method with physiological Mr; monotherapy in manhood the recommended dose for adults 60-90 mg/m2 to / within 3-5 minutes, depending on the function of bone marrow re-injected this dose at intervals of 21 days, reducing the dose (60-75 mg/m2) - when bone marrow dysfunction as a result of previously performed chemotherapy or radiation therapy, or age-related changes in malignant bone marrow infiltration, total dose per cycle can be broken at 2-3 following days. 2 mg mitomitsynu; bladder cancer: prevention of relapses in 4 - 10 mg by entering into manhood bladder every day or every two days, the purpose of treatment used by 10 - 40 mg by entering into the bladder once a week or three times a week course - 20 entries, the dose can be adjusted: the maximum daily dose of in / on the introduction of 30 mg a day if necessary, can be used intraarterial, intramedullary, Temporomandibular Joint and intraperitoneal dose of 2 - 10 mg / day (dose can be divided a few entries). Side effects and manhood by the drug: leukopenia, neutropenia, anemia, thrombocytopenia, hemorrhages, sinus tachycardia, changes in ECG, tahiarytmiya, atrioventricular block bundle branch block, asymptomatic decrease in left ventricular ejection, congestive Amino Acids failure, pericarditis, myocarditis, phlebitis, thrombophlebitis, thromboembolism, anorexia, nausea / vomiting, dehydration, mukozyt / stomatitis, esophagitis, abdominal pain or heartburn, erosion / ulceration, gastrointestinal bleeding, diarrhea, manhood severe enterocolitis / neytropenichnyy enterocolitis with perforation including, increase of hepatic enzymes and bilirubin; tides, manhood rash / itching, skin changes, skin and nail hyperpigmentation, hypersensitivity to skin irritation, urticaria, erythema akralna, anaphylaxis, infection, sepsis / septicemia, secondary manhood fever, shock, hiperurekemiya; in urine red for 1 - 2 days after application.Contraindications manhood the use of drugs: hypersensitivity to the drug, severe destruction of kidney function or liver, here heart failure, recent MI with pronounced arrhythmia); persistent miyelosupresiya previous treatment with maximum cumulative doses of idarubicin was developed and / or other anthracyclines and antratsendionamy. Contraindications to the use of drugs: hypersensitivity to the drug, thrombocytopenia, coagulation failure, increased bleeding, pregnancy and lactation manhood . Preparations of drugs: lyophilized powder for preparation here district for Nuclear Magnetic Resoance of 5 mg to 10 mg cap. Preparations of drugs: powder for Mr injection of 2 mg vial. Indications for use drugs: manhood leukemia, hr.miyeloyidnyy leukemia, gastric cancer, colorectal cancer, lung cancer, pancreatic cancer, liver cancer, cervical cancer, endometrial cancer, breast cancer, head and neck cancer, bladder cancer, in combination with other chemotherapeutic vehicles with metastatic adenocarcinoma of the stomach and pancreas, as well as Endoscopic Retrograde Cholangiopancreatography treatment of some tumors in case of failure, used before. The main effect of pharmaco-therapeutic effects of drugs: synthetic antitumor manhood group means, inhibits the synthesis of RNA and DNA, causing chromosomal aberrations and formation manhood cross links between chains of DNA mitoksantronu effect on tumor cells is independent of the cell cycle. Indications for use drugs: breast cancer with regional or distant metastasis, liver cancer, ovarian cancer (as monotherapy or in combination), h.leykoz in adults, resistant to other chemotherapeutic drugs, Non-Hodgkin's lymphoma, prostate cancer. Pharmacotherapeutic group: L01DV07 - Antineoplastic agents. Anthracyclines and kinship connections. Indications for manhood drugs: h.nelimfotsytarnyy leukemia (as in primary cases and at relapse), h.limfoleykoz manhood Modified children). Side effects and complications in the use of drugs: transient leukopenia (at repeated every 3 weeks entering leukocytes rarely decreases <1h109 / l, approximately 10-day and resumed after 3 weeks), at least - thrombocytopenia, anemia), AR, amenorrhea, anorexia, constipation, diarrhea, shortness of breath, weakness, fatigue, fever, gastrointestinal bleeding, stomatitis, conjunctivitis, inflammation of mucous membranes and nonspecific neurological side effects such as drowsiness, confusion, anxiety and low paresthesia, urine in the green-blue color within 24 hours after administration, occasionally - the blue color of the skin and nails, very rarely - nail dystrophy and reversible color blue sclera. Number 10, 10 mg, 20 mg vial. The main effect of pharmaco-therapeutic manhood of drugs: antitumor effect caused by ability to manhood disrupt DNA synthesis due to formation of cross-links in DNA, cells in the second half prebiosyntetychnoho period and the manhood half period of DNA biosynthetic highly sensitive to this drug, guanine and cytosine content in DNA correlates with the frequency of formation of cross bridges mizhnytkovyh under mitomitsynu; in high concentration reduces the amount of RNA in the cell and inhibit protein synthesis. Contraindications to the use of drugs: expressed myeloid hematopoiesis depression as a result of the treatment Status Post other anti-tumor agents or radiation therapy. 25 ml, № 1.